<DOC>
	<DOCNO>NCT00499616</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , carboplatin , cyclophosphamide , etoposide , doxorubicin hydrochloride , work different way stop growth tumor cell , either kill cell stop dividing . Isotretinoin may help neuroblastoma cell become like normal cell , grow spread slowly . Giving combination chemotherapy without isotretinoin surgery may make tumor small reduce amount normal tissue need remove . It yet know treatment regimen effective treat young patient neuroblastoma . PURPOSE : This phase III trial compare different regimen combination chemotherapy surgery without isotretinoin see well work treat young patient neuroblastoma .</brief_summary>
	<brief_title>Combination Chemotherapy Surgery With Without Isotretinoin Treating Young Patients With Neuroblastoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Reduce therapy patient intermediate-risk neuroblastoma maintain 3-year overall survival ( OS ) rate ≥ 95 % use response-based duration therapy algorithm . - Maintain overall 3-year OS rate ≥ 90 % patient within group . - Utilize loss heterozygosity , prospectively , 1p36 11q23 refine risk-stratification treatment assignment , allow patient whose tumor lack chromosomal abnormality receive reduction therapy , compare outcome patient treat COG-A3961 . - Reduce intensity therapy patient 365 &lt; 547 day ( 12-18 month ) age stage 4 neuroblastoma favorable biological feature maintain 3-year event-free survival ( EFS ) rate consistent patient &lt; 1 year age stage 4 neuroblastoma treat COG-A3961 . - Reduce intensity therapy patient 365 &lt; 547 day ( 12-18 month ) age stage 3 MYCN-nonamplified unfavorable histology neuroblastoma maintain 3-year EFS rate consistent patient &lt; 1 year age stage 3 , MYCN-nonamplified , unfavorable histology neuroblastoma treat COG-A3961 . - Reduce surgical morbidity patient stage 4S neuroblastoma allow biopsy , rather complete surgical resection , primary tumor . - Systematically study outcome patient stage 4S neuroblastoma unable undergo biopsy biology-based risk assignment . - Determine extent surgical resection correlate maintenance local control , EFS and/or OS rate , surgical complication rate . Secondary - Determine result standard retrieval approach patient residual disease 8 course initial therapy . - Determine result standard retrieval approach patient progressive , nonmetastatic disease . - Identify additional biological surrogate marker disease relapse and/or metastatic progression . - Describe neurologic outcome patient paraspinal neuroblastoma primary tumor . - Correlate surgical biopsy technique adequacy tissue acquisition biologic study complication associate biopsy procedure . - Prospectively validate prognostic ability International Neuroblastoma Risk Group image-defined risk factor system , compare institutional assessment image-defined risk factor central review . OUTLINE : This multicenter study . Patients assign 1 4 treatment group risk-stratification base age , stage ( INSS stage 2 , 3 , 4 , 4S ) , MYCN status ( amplify vs amplify ) , histopathologic classification , tumor DNA index . - Initial chemotherapy : Courses initial chemotherapy administer every 21 day accord group assignment outline : - Course 1 : Patients receive carboplatin IV 1 hour day 1 etoposide IV 1 hour day 1-3 . - Course 2 : Patients receive carboplatin IV 1 hour , cyclophosphamide IV 1 hour , doxorubicin hydrochloride IV 15 minute day 1 . - Course 3 : Patients receive cyclophosphamide IV 1 hour day 1 etoposide IV 1 hour day 1-3 . - Course 4 : Patients receive carboplatin IV 1 hour doxorubicin hydrochloride IV 15 minute day 1 etoposide IV 1 hour day 1-3 . - Course 5 : Patients receive cyclophosphamide IV 1 hour day 1 etoposide IV 1 hour day 1-3 . - Course 6 : Patients receive carboplatin IV 1 hour , cyclophosphamide IV 1 hour , doxorubicin hydrochloride IV 15 minute day 1 . - Course 7 : Patients receive carboplatin IV 1 hour day 1 etoposide IV 1 hour day 1-3 . - Course 8 : Patients receive cyclophosphamide IV 1 hour doxorubicin hydrochloride IV 15 minute day 1 . - Group 1 : Patients receive 2 course initial chemotherapy . Patients partial response ( PR ) ( 50-90 % reduction volume ) chemotherapy proceed observation . Patients without PR receive 2-6 additional course chemotherapy ( begin course 3 ) . Patients achieve PR additional chemotherapy proceed retrieval chemotherapy . - Group 2 : Patients receive 4 course initial chemotherapy . Patients PR chemotherapy proceed observation . Patients without PR receive 2-4 additional course chemotherapy ( begin course 5 ) . Patients achieve PR additional chemotherapy proceed retrieval chemotherapy . - Group 3 : Patients receive 8 course initial chemotherapy . Patients 12 month age stage 3 , 4 , 4S ( include liver metastasis ) disease achieve good PR ( VGPR ) ( &gt; 90 % reduction volume primary tumor resolution metastatic disease ) chemotherapy proceed observation . Patients 12-18 month age stage 3 4 disease achieve VGPR proceed isotretinoin therapy . Patients achieve VGPR proceed retrieval chemotherapy . - Group 4 : Patients receive 8 course initial chemotherapy . If VGPR achieve follow 8 course first-line chemotherapy +/- surgery , retrieval chemotherapy cyclophosphamide/topotecan 2-6 course administer VGPR achieve combination chemotherapy surgery . - Retrieval chemotherapy* : Patients receive cyclophosphamide IV 30 minute topotecan IV 30 minute day 1-5 . Treatment repeat every 21 day 6 course . - Groups 1 2 : Patients PR 2-6 course retrieval chemotherapy proceed observation . Patients without PR 2-6 course retrieval chemotherapy remove protocol therapy . - Group 3 : Patients 12 month age stage 4 disease VGPR retrieval chemotherapy proceed observation . Patients 12-18 month age stage 3 4 disease achieve VGPR retrieval chemotherapy proceed isotretinoin therapy . Patients achieve VGPR retrieval chemotherapy remove protocol therapy . - Group 4 : Group 4 patient fail achieve VGPR develop progressive , non-metastatic disease within 3 year study enrollment proceed isotretinoin therapy . Isotretinoin also administer follow Group 4 patient : - Age 365 &lt; 547 day diagnosis , INSS stage 3 , MYCN-NA , unfavorable histology , ploidy - Age 365 &lt; 547 day diagnosis , INSS stage 4 , MYCN-NA , favorable histology , DI &gt; 1 NOTE : *Patients previously receive cyclophosphamide topotecan achieve first PR/VGPR eligible Retrieval Therapy . - Surgery : With exception patient INSS 4S disease , patient undergo surgery remove much primary tumor involve lymph node safely accomplish . Reassessment definitive surgery ( patient undergo biopsy partial resection diagnosis ) make completion schedule chemotherapy ( course 2 group 1 , course 4 group 2 , course 8 group 3 4 ) . - Isotretinoin therapy : Beginning 3-4 week completion chemotherapy 2 week post-operatively ( patient undergo surgical resection ) , patient receive oral isotretinoin twice daily day 1-14 . Treatment repeat every 28 day 6 course absence disease progression unacceptable toxicity . After completion study therapy , patient follow periodically 10 year . Data patient low-risk disease observe follow surgical resection enrol ANBL0531 , collect study objective .</detailed_description>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Antineoplastic Agents</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<mesh_term>Isotretinoin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm neuroblastoma , ganglioneuroblastoma , ganglioneuroma/maturing subtype Newly diagnose disease Intermediaterisk disease Needle biopsies involve bone marrow sufficient INPC histologic classification Meets 1 follow criterion : Group 1 International Neuroblastoma Staging System ( INSS ) stage 2A/2B ; &lt; 50 % resected biopsy ; ≤ 12 year age ; MYCNnot amplify ( NA ) ; histology ploidy ; normal 1p 11q INSS stage 3 ; age &lt; 365 day ; MYCNNA ; favorable histology ( FH ) ; hyperdiploid ( DI ) &gt; 1 ; normal 1p 11q INSS stage 3 ; 365 day 12 year age ; MYCNNA ; FH ; normal 1p 11q INSS stage 4S ; age &lt; 365 day ; MYCNNA ; FH ; DI &gt; 1 ; normal 1p 11q ; clinically symptomatic Group 2 INSS stage 2A/2B ; &lt; 50 % resected biopsy ; ≤ 12 year age ; MYCNNA ; histology ploidy ; 1p loss heterozygosity ( LOH ) and/or unb11q LOH ( data miss either ) INSS stage 3 ; age &lt; 365 day ; MYCNNA ; FH ; DI &gt; 1 ; 1p LOH and/or unb11q LOH ( data miss either ) INSS stage 3 ; age &lt; 365 day ; MYCNNA ; DI = 1 and/or unfavorable histology ( UH ) ; normal 1p 11q INSS stage 3 ; 365 day 12 year age ; MYCNNA ; FH ; 1p LOH and/or unb11q LOH ( data miss either ) INSS stage 4 ; age &lt; 365 day ; MYCNNA ; FH ; DI &gt; 1 ; normal 1p 11q INSS stage 4S ; age &lt; 365 day ; MYCNNA ; either UH ploidy FH DI = 1 ; normal 1p 11q INSS stage 4S ; age &lt; 365 day ; MYCNNA ; FH ; DI &gt; 1 ; 1p LOH and/or unb11q LOH ( data miss either ) ; clinically symptomatic Group 3 INSS stage 3 ; age &lt; 365 day ; MYCNNA ; DI = 1 and/or UH ; 1p LOH and/or unb11q LOH ( data miss either ) INSS stage 3 ; age 365 &lt; 547 day ; MYCNNA ; UH ; ploidy ; 1p 11q INSS stage 4 , age &lt; 365 day ; MYCNNA ; DI = 1 and/or UH ; 1p 11q INSS stage 4 ; age &lt; 365 day ; MYCNNA ; FH ; DI &gt; 1 ; 1p LOH and/or unb11q LOH ( data miss either ) INSS stage 4 ; age 365 &lt; 547 day ; MYCNNA ; FH ; DI &gt; 1 ; 1p 11q INSS stage 4S ; age &lt; 365 day ; MYCNNA ; UH ploidy FH DI = 1 ; 1p LOH and/or unb11q LOH ( data miss either ) INSS stage 4S ; age &lt; 365 day ; unknown incomplete biologic feature Group 4 INSS stage 3 , age &lt; 365 day , MYCNNA , either DI = 1 and/or UH , 1p LOH and/or unb11q LOH ( data miss either ) INSS stage 3 , age 365 &lt; 547 day , MYCNNA , UH , ploidy , 1p 11q 3 INSS stage 4 , age &lt; 365 day , MYCNNA either DI = 1 and/or UH , 1p 11q INSS stage 4 , age &lt; 365 day , MYCNNA , FH , DI &gt; 1 , 1p LOH and/or unb11q LOH ( data miss either ) INSS stage 4 , age 365 &lt; 547 day , MYCNNA , FH , DI &gt; 1 , 1p 11q INSS stage 4S , age &lt; 365 day , MYCNNA , either UH ploidy FH DI = 1 1p LOH and/or unb11q LOH ( data miss either ) INSS stage 4S , age &lt; 365 day , unknown MYCN , histology , and/or ploidy Must already enrol protocol COGANBL00B1 Simultaneous enrollment COGANBL00B1 study allow clinical situation emergent treatment may indicate include , limited , follow criterion : Epidural intraspinal tumor exist impend neurologic impairment Periorbital calvarialbased lesion exist impend cranial nerve impairment Anatomic mechanical compromise critical organ function tumor ( e.g. , abdominal compartment syndrome , urinary obstruction ) Asymptomatic , opinion treat physician , patient 's best interest begin chemotherapy immediately due impend risk neurologic impairment organ dysfunction If patient receives study chemotherapy prior undergoing diagnostic biopsy , biopsy must perform within 96 hour begin study therapy The exception requirement patient stage 4S disease consider ill undergo diagnostic procedure waive requirement diagnostic tissue submission still need enrolled COGANBL00B1 For patient stage 4S disease ill open biopsy obtain tissue diagnosis biologic study consider medically contraindicate , every effort make obtain tumor tissue either fineneedle aspiration metastatic site disease and/or sample involved bone marrow , tumor sample submit MYCN determination Patients require emergent therapy , either prior diagnostic biopsy biology feature available , enrol simultaneously COGANBL00B1 COGANBL0531 receive emergent protocol therapy In emergent circumstance , COGANBL0531 protocol therapy may initiate prior enrollment study long patient neuroblastoma clinical diagnosis , COGANBL0531 eligibility criterion meet , COGANBL0531 Initial Therapy consent sign prior start protocol therapy ; circumstance ANBL0531 enrollment must occur within 4 work day start protocol therapy Clinical situation emergent enrollment treatment may indicate include , limited , follow circumstance : Epidural intraspinal tumor exist impend neurologic impairment Periorbital calvarialbased lesion exist impend cranial nerve impairment Anatomic mechanical compromise critical organ function tumor ( e.g. , abdominal compartment syndrome , urinary obstruction ) Evolving hepatomegaly infant le 2 month age PATIENT CHARACTERISTICS : See Disease Characteristics PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior chemotherapy radiotherapy exception dexamethasone No participation another COG study tumor therapeutic intent</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>regional neuroblastoma</keyword>
	<keyword>disseminate neuroblastoma</keyword>
	<keyword>stage 4S neuroblastoma</keyword>
	<keyword>localize unresectable neuroblastoma</keyword>
	<keyword>localize resectable neuroblastoma</keyword>
</DOC>